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Type 2 Diabetes Mellitus (T2DM) is a metabolic disorder of global concern that is 
primarily characterized by insulin resistance, relative insulin deficiency, and hyperglycemia. G- 
Protein Coupled Receptors (GPCRs), important mediators of cellular signaling responses, have 
been prime targets of drug discovery efforts in various therapeutic areas. Human G-Protein 
Receptor 40 (HGPR40) is highly expressed in the pancreas and has been implicated in the 
regulation of glucose metabolism and pathophysiology of T2DM. For effective control of 
diabetes, combination therapy is being considered because no single drug can completely control 
diabetes and its associated complications. This necessitates the identification of novel drug targets 
including HGPR40 which might permit development of drugs which function differently from 
existing drugs. This project focused on the construction of two chimeric receptor proteins named 
HGPR40.1-715_43.709-1013 (Chimera I) and HGPR40.1-431_43.389-1013 (Chimera II) which 
were made by exchanging domains within trans-membranes regions 6 and 4, of HGPR40 and 
HGPR43 DNA, homologous receptors which vary in amino acid sequence but which have the 
same three-dimensional structure. After PCR amplification of sufficient quantities of the desired 
gene fragments they were ligated together to form the desired recombinant chimeric proteins 
which were cloned into the expression vector pcDNA3.1 in two successive cloning steps. The 
vector contains CMV promoter, multiple cloning sites, neomycin resistance gene etc for high-
level expression in a wide range of mammalian cells. The two full-length chimeras were designed 
to be 6452 bp and 6483 bp by exchanging either the first or the first two external domains of 
HGPR40 with those of HGPR43. The creation of the correct chimeras was verified by both 
agarose gel electrophoresis and PCR analysis. Then chimeric DNA was transformed into 
Escherichia coli to obtain sufficient amounts of DNA for sequencing verification of the desired 
construct. Upon verification, the cloned DNA was to be transfected into cultured mammalian 
kidney (HEK293) cells for expression of the chimeric proteins. A (FLIPR) Fluorometric Imaging 
Plate Reader analysis by our collaborators at Eli Lilly would have been used to measure the 
extent of Ca
2+
 efflux from the endoplasmic reticulum testing a variety of stimulatory molecules to 
obtain an indication of which would activate the receptor. Activation would initiate the internal 
(second messenger cascade) G-protein signaling pathway and result in the secretion of insulin. 
However, transformation of the chimeric membrane receptors into E. coli resulted in altered 
sequences which could not be used for the FLIPR analysis. Expression of membrane proteins in 
E. coli can lead to such gene rearrangements. These experiments will be repeated in the future 
using another type of competent cell designed to prevent genetic re-arrangements. Construction 
of stable clones will permit us to test numerous potential ligands to aid in development of novel 
therapeutic drugs targeting HGPR40 to aid in combating diabetes.  
 
